The GH/IGF-1 system in critical illness

被引：67
作者：
Elijah, Itoro E.
Branski, Ludwik K.
Finnerty, Celeste C.
Herndon, David N. [1 ]
机构：
[1] Univ Texas Med Branch, Dept Surg, Galveston, TX 77550 USA
来源：
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2011年 / 25卷 / 05期
基金：
美国国家卫生研究院;
关键词：
trauma; burns; hypermetabolism; protein wasting; IGFBP-3; hepatic acute care response; gut atrophy; nutrition; mortality; anabolic therapy; GROWTH-FACTOR-I; HORMONE TREATMENT; GENE-TRANSFER; BACTERIAL TRANSLOCATION; CATIONIC LIPOSOMES; MESSENGER-RNA; EXPRESSION; THERAPY; PROTEINS; SERUM;
D O I：
10.1016/j.beem.2011.06.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：759 / 767
页数：9
相关论文
共 74 条
[1]   INVITRO PARACRINE REGULATION OF HUMAN KERATINOCYTE GROWTH BY FIBROBLAST-DERIVED INSULIN-LIKE GROWTH-FACTORS [J].
BARRECA, A ;
DELUCA, M ;
DELMONTE, P ;
BONDANZA, S ;
DAMONTE, G ;
CARIOLA, G ;
DIMARCO, E ;
GIORDANO, G ;
CANCEDDA, R ;
MINUTO, F .
JOURNAL OF CELLULAR PHYSIOLOGY, 1992, 151 (02) :262-268
[2]   CLINICAL USES OF INSULIN-LIKE GROWTH-FACTOR-I [J].
BONDY, CA ;
UNDERWOOD, LE ;
CLEMMONS, DR ;
GULER, HP ;
BACH, MA ;
SKARULIS, M .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (07) :593-601
[3]  
BRANSKI LK, 2009, ANN SURG
[4]  
CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196
[5]   Treatment with growth hormone and insulin-like growth factor-I in critical illness [J].
Carroll, PV .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 15 (04) :435-451
[6]  
Christiansen JS, 2001, J CLIN ENDOCR METAB, V86, P1868
[7]   INSULIN-LIKE GROWTH-FACTOR-I LOWERS PROTEIN OXIDATION IN PATIENTS WITH THERMAL-INJURY [J].
CIOFFI, WG ;
GORE, DC ;
RUE, LW ;
CARROUGHER, G ;
GULER, HP ;
MCMANUS, WF ;
PRUITT, BA .
ANNALS OF SURGERY, 1994, 220 (03) :310-319
[8]  
DAHN MS, 1988, ARCH SURG-CHICAGO, V123, P1409
[9]   Genomic analysis of insulin-like growth factor-I gene transfer in thermally injured rats [J].
Dasu, MRK ;
Herndon, DN ;
Spies, M ;
Perez-Polo, JR .
WOUND REPAIR AND REGENERATION, 2004, 12 (02) :217-224
[10]   Growth hormone therapy in short children born small for gestational age [J].
de Zegher, F ;
Ong, KK ;
Ibáñez, L ;
Dunger, DB .
HORMONE RESEARCH, 2006, 65 :145-152
12345678